Wedbush Equities Analysts Reduce Earnings Estimates for ANRO

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at Wedbush decreased their FY2024 earnings estimates for Alto Neuroscience in a research report issued on Wednesday, November 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($2.60) per share for the year, down from their prior forecast of ($2.58). Wedbush currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.63) per share. Wedbush also issued estimates for Alto Neuroscience's Q4 2024 earnings at ($0.66) EPS, FY2026 earnings at ($2.25) EPS and FY2027 earnings at ($2.32) EPS.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.05.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a research report on Wednesday, October 23rd. RODMAN&RENSHAW downgraded Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Stifel Nicolaus lowered their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Finally, Rodman & Renshaw downgraded Alto Neuroscience from a "buy" rating to a "neutral" rating in a research report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $20.00.

Alto Neuroscience Trading Down 1.7 %

Shares of NYSE ANRO traded down $0.08 during mid-day trading on Friday, hitting $4.52. The company had a trading volume of 257,702 shares, compared to its average volume of 374,899. The business's 50-day simple moving average is $9.86 and its 200 day simple moving average is $11.41. The company has a quick ratio of 19.85, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1-year low of $3.61 and a 1-year high of $24.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. FMR LLC boosted its holdings in Alto Neuroscience by 1.4% during the third quarter. FMR LLC now owns 2,363,056 shares of the company's stock valued at $27,033,000 after acquiring an additional 32,040 shares during the period. RA Capital Management L.P. bought a new position in Alto Neuroscience during the first quarter worth $21,267,000. Jennison Associates LLC raised its stake in Alto Neuroscience by 80.3% during the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company's stock valued at $9,521,000 after purchasing an additional 370,612 shares during the last quarter. Vestal Point Capital LP raised its stake in Alto Neuroscience by 4.8% during the 3rd quarter. Vestal Point Capital LP now owns 650,000 shares of the company's stock valued at $7,436,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience in the 1st quarter valued at $9,788,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.